Mei pharma, inc. (MEIP)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'12Mar'12Dec'11Sep'11
Net (loss) income

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-20,512

-

-20,754

-24,313

-28,321

-32,694

-35,573

-34,030

-31,245

-27,148

0

0

0

-

-

-

-

Cash flows from operating activities:
Net loss

-24,487

-37,513

-5,271

-16,819

-39,125

-27,718

-45,822

-40,068

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of warrant liability

22,920

9,987

41,863

27,632

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Share-based compensation

6,882

6,846

6,738

6,562

5,863

5,119

4,158

3,217

2,747

2,591

2,563

2,304

2,541

2,566

2,690

2,723

2,700

3,129

3,583

4,223

4,943

5,059

4,981

4,747

0

0

0

511

0

0

0

Gain on adjustment to fair value of derivatives

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,139

0

0

0

Financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

406

0

0

0

Depreciation and amortization

118

112

98

80

65

54

52

53

83

83

85

85

55

57

57

58

61

63

63

64

64

57

53

50

0

0

0

13

0

0

0

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-549

145

-1,536

849

2,299

1,647

3,030

-172

-1,902

-1,896

-1,100

927

1,654

1,881

1,145

329

510

254

243

5

-269

-360

-249

41

0

0

0

-126

0

0

0

Accounts payable

523

880

1,543

1,144

710

1,069

804

3,058

1,017

707

2

-494

-224

-66

496

216

-2,245

-1,704

-858

-845

2,011

1,343

554

1,171

0

0

0

266

0

0

0

Accrued liabilities

-459

-1,181

368

1,105

3,570

1,536

-278

669

-1,096

792

839

-1,148

152

8

-446

337

-368

-1,800

-1,323

1,188

1,109

3,111

3,289

1,770

0

0

0

259

0

0

0

Deferred revenue

-3,124

-2,977

6,166

6,986

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-42,918

-43,965

-30,685

-29,423

-24,842

-19,739

-27,289

-21,035

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Cash flows from investing activities:
Net cash (used in) provided by operating activities

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-3,323

-

-21,116

-24,879

-27,099

-28,069

-27,177

-24,100

-22,119

-19,451

0

0

0

-

-

-

-

Purchases of property and equipment

-

-

-

-

-

-

-

-

-

-

-

51

0

0

0

-

-

-

-

-

-

-

-

50

0

0

0

-

-

-

-

Purchases of short-term investments

115,223

115,084

79,697

64,655

124,052

118,965

114,171

114,233

39,950

45,081

45,068

60,123

65,158

50,146

55,167

55,238

45,204

50,221

85,204

70,077

0

0

0

-

-

-

-

-

-

-

-

Proceeds from maturity of short-term investments

104,727

104,508

104,411

89,190

79,192

69,400

69,590

69,906

55,062

50,083

50,115

50,097

55,153

50,158

50,197

65,214

60,148

65,156

70,083

60,036

0

0

0

-

-

-

-

-

-

-

-

Net cash (used in) provided by investing activities

-11,291

-10,626

24,497

24,318

-45,067

-49,737

-44,581

-44,327

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-4,976

-

14,942

14,930

-15,136

-10,056

-15,093

-35,105

-25,065

-35,066

0

0

0

-

-

-

-

Proceeds from exercise of stock options

125

377

401

372

459

207

352

329

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of warrants

-

-

-

1,118

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock

0

0

0

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

9,831

0

0

0

Collection of common stock proceeds receivable

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of RSU tax withholdings in exchange for

-

-

-

324

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

406

0

0

0

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

54,221

54,481

6,054

1,386

71,137

70,885

71,030

70,213

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net decrease in cash and cash equivalents

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-

4,851

-5,446

-7,711

-6,831

-2,379

-2,647

1,376

-4,087

-7,885

-6,174

-9,983

835

4,945

795

-16,105

-14,463

-21,796

0

0

0

2,344

0

0

0

Supplemental cash flow information:
Income taxes paid

-1

-1

-1

-1

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-